Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by inforcashon Oct 01, 2010 9:23pm

453 Views

Post# 17520541

RE: RE: RE: RE: RE: RE: Shakedown!!

Guys, forgive my ignorance, but I don't see the similarities between the two. NRI was a one-trick pony with a single drug for an indication that is already crowded with competition. Haven't followed the stock, and am not current on NRI news, but I had a conversation with a higher-up just under a year ago, and I got the impression even he thought it wasn't a wonder drug but a simple stepping stone to start generating $$$$... TH on the otherhand has a drug where the HIV community is pressing--and thats not considering the additional indications and/or off label.

I'm curious to know where you see the similarities, since I'm very top-heavy in TH.

Thanks for sharing.

IFC

Bullboard Posts

Cybin launches new program phase to treat Major Depressive Disorder